CALGARY, ALBERTA--(CCNMatthews - Sept. 11, 2006) - Resverlogix Corp. (“Resverlogix”) (TSX:RVX), is pleased to announce today that it has chosen lead molecules for first administration in man studies. The pharmacokinetic results of the molecule(s) in humans will guide and accelerate the further clinical development as to pharmacological doses needed to significantly raise ApoA-I, the core protein in the good cholesterol (HDL). Administration of low doses, so called microdosing, is a highly attractive technique for pharmaceutical companies which can improve predictability, efficiency and expedience of subsequent human trials.
